Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Screen patients for AATD: position statement from TSANZ

Recommendation to lift PBS restrictions on ICS+LABA access in children

This surgeon wants smokers to be banned from having surgery – until they quit

Experts question blood eosinophil cut-offs in GINA, GOLD

Urgent need for a national health protection strategy against bushfire smoke

Asthma

New PBS listings give relief for severe asthma

31 Jan 2017

The government has announced $130 million in federal funding to subsidise two asthma medications on the Pharmaceutical Benefits Scheme (PBS). The anti-interleukin-5 (anti-IL-5) therapy mepolizumab (Nucala® Glaxo SmithKline) is now available on the PBS under section 100 as an add-on treatment for people aged 12 and over with severe refractory eosinophilic asthma. It is given ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories